259 related articles for article (PubMed ID: 38348118)
1. Pediatric oncology drug development and dosage optimization.
Cheung SYA; Hay JL; Lin YW; de Greef R; Bullock J
Front Oncol; 2023; 13():1235947. PubMed ID: 38348118
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
4. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
5. Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse.
Shebley M; Menon RM; Gibbs JP; Dave N; Kim SY; Marroum PJ
J Clin Pharmacol; 2019 May; 59(5):625-637. PubMed ID: 30562405
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
7. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
Lee DP; Skolnik JM; Adamson PC
J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
[TBL] [Abstract][Full Text] [Related]
8. Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective.
Murphy R; Halford S; Symeonides SN
Front Oncol; 2023; 13():1144056. PubMed ID: 36937434
[TBL] [Abstract][Full Text] [Related]
9. Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.
Gao W; Liu J; Shtylla B; Venkatakrishnan K; Yin D; Shah M; Nicholas T; Cao Y
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):691-709. PubMed ID: 37969061
[TBL] [Abstract][Full Text] [Related]
10. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization.
Yang P; Li D; Lin R; Huang B; Yuan Y
Stat Med; 2024 May; ():. PubMed ID: 38747472
[TBL] [Abstract][Full Text] [Related]
11. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
Mittapalli RK; Yin D; Beaupre D; Palaparthy R
Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
[TBL] [Abstract][Full Text] [Related]
12. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
14. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
15. Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
Pantoja K; Lanke S; Munafo A; Victor A; Habermehl C; Schueler A; Venkatakrishnan K; Girard P; Goteti K
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1371-1381. PubMed ID: 35852048
[TBL] [Abstract][Full Text] [Related]
16. Dose Optimization of Vancomycin Using a Mechanism-based Exposure-Response Model in Pediatric Infectious Disease Patients.
Jung WJ; Park JH; Goo S; Chae JW; Kim J; Shin S; Yun HY
Clin Ther; 2021 Jan; 43(1):185-194.e16. PubMed ID: 33358258
[TBL] [Abstract][Full Text] [Related]
17. Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.
Mittapalli RK; Guo C; Drescher SK; Yin D
Cancer Chemother Pharmacol; 2022 Sep; 90(3):207-216. PubMed ID: 35965268
[TBL] [Abstract][Full Text] [Related]
18. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
20. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs.
Li C; Sun H; Cheng C; Tang L; Pan H
Contemp Clin Trials Commun; 2022 Dec; 30():100990. PubMed ID: 36203850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
